Latest From TopiVert Ltd.
The US FDA has issued a complete response letter for KPI-121 but Kala hopes to resubmit the drug during the first half of next year backed by data from the ongoing STRIDE 3 study.
A mixed set of results from a Phase IIb/III trial of TOP1630 has not deterred the privately-held firm which maintains that the anti-inflammatory kinase inhibitor is a promising treatment.
As widely anticipated, Takeda has reached an agreement to divest an ex-Shire ophthalmology drug, as it streamlines the combined post-acquisition business to focus on core therapeutic pillars.
The London-based group has begun a Phase IIb/III study evaluating TOP1630 which has a safety and tolerability profile that could prove superior to current treatments such as Allergan's market leader Restasis.
- Topical Delivery
- Drug Delivery
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- TopiVert Ltd.
- Senior Management
- Steve Webber, CSO
- Contact Info
Phone: 207 594 1213
Imperial Incubator, Level 1 Bessemer Blg
London, SW7 2BP
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.